期刊文献+

质谱技术筛选肾上腺皮质肿瘤差异蛋白研究 被引量:1

Identification of differentially expressed proteins in adrenal tumor by mass spectrometry
暂未订购
导出
摘要 目的比较正常肾上腺组织、肾上腺皮质腺瘤组织和肾上腺皮质癌组织的蛋白质组学差异,探讨肾上腺皮质肿瘤的鉴别诊断和肾上腺皮质癌的发病、转移机制以及治疗靶点。方法分别提取9例正常肾上腺皮质组织、9例肾上腺皮质腺瘤标本以及9例肾上腺皮质癌标本总蛋白,蛋白经纯化后用固相p H梯度双向凝胶电泳分离肾上腺皮质癌和肾上腺皮质腺瘤组织蛋白质,银染显色,通过PDQUEST 2DE软件分析获取双向凝胶电泳图谱,找出差异表达的蛋白质点。切取差异蛋白质点进行MALDI TOF/TOF质谱鉴定,获取肽质指纹图谱并查询Swiss Prot数据库寻找匹配蛋白质。结果所获得的双向电泳银染图谱重复性较好,正常肾上腺皮质组织蛋白质点约为(2 247±87),肾上腺皮质腺瘤组织蛋白质点数约为(2 375±142),肾上腺皮质癌组织蛋白质点数约为(2 143±107)。在三组组织中,发现表达递减的蛋白有ATP合酶α亚单位(ATPA)、线粒体1Q补体结合蛋白(C1QBP)、组织蛋白酶D(CATD);而14-3-3ζ/δ在腺癌组中表达最低,在腺瘤组中表达最高;PI-PLC X蛋白结构域3在三组间依次递增(P<0.01)。结论正常肾上腺组织、肾上腺皮质腺瘤和肾上腺皮质癌差异表达的蛋白与能量代谢、组织结构以及一些作用蛋白酶有关,表达差异的蛋白在肾上腺皮质肿瘤中参与肿瘤的形成及侵袭作用,其可能可作为潜在的鉴别肾上腺皮质肿瘤良恶性的分子标志,成为肿瘤的生物治疗靶点。 Objective To compare the proteomics discrepancies among normal adrenal tissue, adrenal adenomas, adrenal cortical carcinoma, thereby to discover the differential diagnosis of adrenal cortical tumors and the onset of adrenal cortical carcinoma, and to investigate the transfer mechanism and therapeutic targets of adrenal cortical carcinoma. Methods Total protein was extracted from nine normal adrenal tissue, nine adrenocortical adenoma tissue samples and nine adrenocortical carcinoma samples, respectively. Immobilized pH gradient two-dimensional polyacrylamide gel eleetrophoresis was used to separate the total protein of adrenocortical adenoma tissue samples and adrenocortical carcinoma samples after protein was purified, imageMaster 2DE software was used to find out differential protein after silver staining. Then, MALDI TOF/TOF mass spectrometric identification of differential protein spots was conducted. Peptide mass fingerprints and query were achieved to find out matching proteins in the SwissProt database. Results Dielectrophoresis silver staining map had good repeatability, protein spots of normal adrenal tissue, adrenocorti- cal adenoma tissue and adrenal cortical carcinoma tissue were (2 247 ±87), (2 375 ±142) and (2 143 ±107), respectively. The expression of ATP synthase (ATPA), mitochondria 1 Q complement binding protein (C1 QBP), cathepsin D (CATD)in three groups were diminishing, while the expression of PI-PLC X protein was increased, the cancer group had the lowest expression of 14 -3 -3ζ , and the adenoma group had the highest expression. Conclusions The differentially expressed proteins among the three groups are associate with energy metabolism, organizational structure and some of the effects of protease, they are involved in tumor formation and invasion of tumors in the adrenal cortex, and may be some potential molecular markers to identify benign and malignant adrenal tumor, and become therapeutic target of cancer.
出处 《内科》 2015年第6期759-764,共6页 Internal Medicine
基金 国家自然科学基金(81060220) 广西中医药科技专项立项课题(GZKZ110-109)
关键词 肾上腺皮质肿瘤 恶性 良性 蛋白质组学 生物学标记物 Adrenocortical tumors Benign Malignant Proteomics Biomarker
  • 相关文献

参考文献14

  • 1Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors [ J]. Cancer, 2008, 113 ( 11 ) : 3130 - 3136.
  • 2Chagpar R, Siperstein AE, Berber E. Adrenocortical cancer update [ J ]. Surg Clin North Am,2014,94 ( 3 ) :669 - 687.
  • 3陈平,谢锦云,梁宋平.双向凝胶电泳银染蛋白质点的肽质谱指纹图分析[J].生物化学与生物物理学报,2000,32(4):387-391. 被引量:36
  • 4Jain M, Zhang L, He M, et al. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma[J]. En- docr Relat Cancer,2013,20(3 ) :361 - 370.
  • 5Kutikov A, Mallin K, Canter D, et al. Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database[J]. J Urol,2011, 186(3 ) :805 - 810.
  • 6Patel D, Boufraqech M, Jain M, et al. MiR-34a and miR- 483-5p are candidate serum biomarkers for adrenoeortical tumors [ J ]. Surgery, 2013,154 ( 6 ) : 1224 - 1228, discussion 1229.
  • 7Domenis R, Bisetto E, Rossi D, et al. Glucose-modulated mitochondria adaptation in tumor cells : a focus on ATP syn- thase and inhibitor Factor 1 [ J ]. Int J Mol Sci, 2012, 13(2) :1933 - 1950.
  • 8Pan J, Sun LC, Tao YF, et al. ATP synthase ecto-alpha-subunit : a novel therapeutic target for breast cancer [ J ]. J Transl Med .2011.9:211.
  • 9Wei Y, Vellanki RN, Coyaud E, et al. CHCHD2 is Co-am- plified with EGFR in NSCLC and Regulates Mitochondrial Function and Cell Migration [ J]. Mol Cancer Res, 2015, 13(7) :1119 - 1129.
  • 10Shin IY, Sung NY, Lee YS, et al. The expression of multi- pie proteins as prognostic factors in colorectal cancer: ca- thepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67 [ J ]. Gut Liver, 201 d, 8 ( 1 ) : 13 - 23.

二级参考文献16

  • 1Neal CL, Yu D. 14-3-3zeta as a prognostic marker and therapeu-tic target for cancer [J]. Expert Opin Ther Targets,2010,14(12):1343-1354.
  • 2Choi JE?Hur W,Jung CK,et al. Silencing of 14-3-3zeta over-ex-pression in hepatocellular carcinoma inhibits tumor growth andenhances chemosensitivity to cis-diammined dichloridoplatium[J]. Cancer Lett,2011,303(2) :99-107.
  • 3Niemantsverdriet M, Wagner K,Visser M, et al. Cellular func-tions of 14-3-3 zeta in apoptosis and cell adhesion emphasize itsoncogenic character[J], Oncogene,2008,27(9) : 1315-1319.
  • 4Kambach DM, Sodi VL’Lelkes PI,et al. ErbB2, FoxMl and 14-3-3^ prime breast cancer cells for invasion in response to ionizingradiation[J]. Oncogene, 2013 ,doi: 10. 1038/onc. 2012. 629.
  • 5Bajpai U?Sharma R,Kausar T,et al. Clinical significance of 14-3-3 zeta in human esophageal cancer [J]. Int J Biol Markers,2008,23(4):231-237.
  • 6Anna Bergamaschi,Jonna Frasor,Kristina Borgen,et al. 14-3-3^as a predictor of early time to recurrence and distant metastasisin hormone receptor-positive and -negative breast cancers [J].Breast Cancer Res Treat,2013,137(3) :689-696.
  • 7Schuster TB, Costina V, Findeisen P, et al. Identification and func-tional characterization of 14-3-3 in TLR2 signaling[J]. J ProteomeRes,2011,10(10):4661-4670.
  • 8Ohman T,Lietzen N, Vlimki E,et al. Cytosolic RNA recognitionpathway activates 14-3-3 protein mediated signaling and caspase-dependent disruption of cytokeratin network in human keratino-cytes[J]. J Proteome Res,2010,9(3) : 1549-1564.
  • 9Huang XY,Ke AW,Shi GM’et al. aB-Crystallin complexes with14-3-3^ to induce epithelial-mesenchymal transition and resist-ance to sorafenib in hepatocellular carcinoma [J], Hepatology,2013,57(6):2235-2247.
  • 10Mu FT,Cranmer SL, Andrews RK,et al. Functional associationof phosphoinositide-3-kinase with platelet glycoprotein Ibalpha,the major ligand-binding subunit of the glycoprotein Ib-IX-Vcomplex[J]. J Thromb Haemost,2010,8(2) :324-330.

共引文献39

同被引文献14

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部